The Biologics Research department of Sanofi, based at the research center in Vitry-sur-Seine, has the mission of developing therapeutic antibodies in the context of different diseases. As the discovery of potential targets with higher therapeutic implication is advancing, and more and more complex targets are being identified, there is a demand for correspondingly more complex antibodies with sometimes quite rare characteristics. To meet this demand, it is crucial for Biologics Research to increase the throughput of antibody screening and selection processes in order to generate a more diverse panel of antibody hits which in turn will increase the chance of finding antibodies with those rare characteristics.

More information : 2018-microfluidics-proposal.pdf